How long does it take for pazopanib to be effective in late-stage kidney cancer?

Pazopanib (Pazopanib) belongs to oral multi-targeted tyrosine kinase inhibitors (a type of targeted therapy), which can inhibit tumor angiogenesis and cell proliferation. It is an approved drug for the treatment of advanced renal cancer. However, everyone's response to the drug is different, and it is difficult to accurately determine the specific effect and time of effect of pazopanib on an individual. Clinical studies have shown pazopanib to be more effective than placebo in treating advanced renal cell carcinoma. On average, patients who took pazopanib lived without worsening of their disease for 9.2 months, compared with 4.2 months for those who took a placebo.